Skip to main content

Table 3 Association between NCAPG expression and clinicopathologic characteristics of LUAD patients

From: NCAPG promotes the progression of lung adenocarcinoma via the TGF-β signaling pathway

Clinical characteristics

NCAPG

p-value

Low expression

High expression

Age (y)

 ≥ 65

74

86

0.407

 < 65

54

78

Sex

 Male

63

87

0.556

 Female

65

77

Clinical stage

 I

79

71

0.004

 II

28

44

 III & IV

21

49

T classification

 T1

47

41

0.091

 T2

66

98

 T3 & T4

15

25

N classification

 N0

92

92

0.006

 N1 & N2 & N3

36

72

Metastasis

 No

125

148

0.011

 Yes

3

16

  1. T for extent of the primary tumor; N for involvement of lymph nodes
  2. T1: Tumor ≤ 3 cm; T2: Tumor > 3 but ≤ 5 cm or tumor involving visceral pleura, main bronchus (not carina), atelectasis to hilum; T3: Tumor > 5 but ≤ 7 cm or invading chest wall, pericardium, phrenic nerve or or separate tumor nodule(s) in the same lobe; T4: Tumor > 7 cm or tumor invading: mediastinum, diaphragm, heart, great vessels, recurrent laryngeal nerve, carina, trachea, esophagus, spine or tumor nodule(s) in a different ipsilateral lobe
  3. N0: No regional node metastasis; N1: Metastasis in ipsilateral pulmonary or hilar nodes; N2: Metastasis in ipsilateral mediastinal/subcarinal nodes; N3: Metastasis in contralateral mediastinal/hilar, or suprclavicular nodes
Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us